Biogen Inc. [NASDAQ: BIIB] gained 39.85% on the last trading session, reaching $276.61 price per share at the time. The company report on September 27, 2022 that LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EARLY ALZHEIMER’S DISEASE.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
ALL KEY SECONDARY ENDPOINTS ALSO MET, DEMONSTRATING HIGHLY STATISTICALLY SIGNIFICANT RESULTS.
PROFILE OF AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA) INCIDENCE WAS WITHIN EXPECTATIONS.
Biogen Inc. represents 145.90 million in outstanding shares, while the company has a total market value of $41.09 billion with the latest information. BIIB stock price has been found in the range of $265.02 to $283.44.
If compared to the average trading volume of 906.14K shares, BIIB reached a trading volume of 16205393 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Biogen Inc. [BIIB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BIIB shares is $234.14 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BIIB stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Robert W. Baird have made an estimate for Biogen Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on September 28, 2022. While these analysts kept the previous recommendation, Mizuho raised their target price from $207 to $270. The new note on the price target was released on September 28, 2022, representing the official price target for Biogen Inc. stock. Previously, the target price had yet another raise from $217 to $360, while BMO Capital Markets kept a Outperform rating on BIIB stock. On April 18, 2022, analysts increased their price target for BIIB shares from 235 to 265.
The Average True Range (ATR) for Biogen Inc. is set at 11.55, with the Price to Sales ratio for BIIB stock in the period of the last 12 months amounting to 3.86. The Price to Book ratio for the last quarter was 3.40, with the Price to Cash per share for the same quarter was set at 32.30. Price to Free Cash Flow for BIIB in the course of the last twelve months was 15.84 with Quick ratio for the last quarter at 1.70.
Trading performance analysis for BIIB stock
Biogen Inc. [BIIB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 38.76. With this latest performance, BIIB shares gained by 40.33% in over the last four-week period, additionally plugging by 28.69% over the last 6 months – not to mention a drop of -2.85% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BIIB stock in for the last two-week period is set at 80.91, with the RSI for the last a single of trading hit 86.42, and the three-weeks RSI is set at 76.16 for Biogen Inc. [BIIB]. The present Moving Average for the last 50 days of trading for this stock 209.48, while it was recorded at 213.71 for the last single week of trading, and 212.71 for the last 200 days.
Biogen Inc. [BIIB]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Biogen Inc. [BIIB] shares currently have an operating margin of +27.54 and a Gross Margin at +75.03. Biogen Inc.’s Net Margin is presently recorded at +14.96.
Return on Equity for this stock inclined to 14.41, with Return on Assets sitting at 6.42.
Biogen Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.70 and a Current Ratio set at 1.90.
Biogen Inc. [BIIB]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BIIB. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Biogen Inc. go to -6.12%.
An analysis of insider ownership at Biogen Inc. [BIIB]
There are presently around $33,914 million, or 87.10% of BIIB stock, in the hands of institutional investors. The top three institutional holders of BIIB stocks are: PRIMECAP MANAGEMENT CO/CA/ with ownership of 15,726,526, which is approximately -0.683% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 14,463,459 shares of the stock with an approximate value of $4.0 billion in BIIB stocks shares; and VANGUARD GROUP INC, currently with $3.28 billion in BIIB stock with ownership of nearly 1.19% of the company’s market capitalization.
Positions in Biogen Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 374 institutional holders increased their position in Biogen Inc. [NASDAQ:BIIB] by around 8,734,750 shares. Additionally, 463 investors decreased positions by around 8,573,417 shares, while 194 investors held positions by with 105,299,189 shares. The mentioned changes placed institutional holdings at 122,607,356 shares, according to the latest SEC report filing. BIIB stock had 73 new institutional investments in for a total of 1,080,850 shares, while 105 institutional investors sold positions of 1,622,523 shares during the same period.